Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Role of HSF1 in cell division, tumorigenesis and therapy: a literature review

O. Fiser, P. Muller

. 2025 ; 20 (1) : 11. [pub] 20250426

Status not-indexed Language English Country England, Great Britain

Document type Journal Article, Review

Grant support
22-17102S Grantová Agentura České Republiky
MH CZ - DRO MMCI, 00209805 Ministerstvo Zdravotnictví Ceské Republiky
project SALVAGE, P JAC; CZ.02.01.01/00/22_008/0 004 644 Ministerstvo Školství, Mládeže a Tělovýchovy

Heat shock factor 1 (HSF1) is the master orchestrator of the heat shock response (HSR), a critical process for maintaining cellular health and protein homeostasis. These effects are achieved through rapid expression of molecular chaperones, the heat shock proteins (HSPs), which ensure correct protein folding, repair, degradation and stabilization of multiprotein complexes. In addition to its role in the HSR, HSF1 influences the cell cycle, including processes such as S phase progression and regulation of the p53 pathway, highlighting its importance in cellular protein synthesis and division. While HSF1 activity offers neuroprotective benefits in neurodegenerative diseases, its proteome-stabilizing function may also reinforce tumorigenic transformation. HSF1 overexpression in many types of cancer reportedly enhances cell growth enables survival, alters metabolism, weakens immune response and promotes angiogenesis or epithelial-mesenchymal transition (EMT) as these cells enter a form of "HSF1 addiction". Furthermore, the client proteins of HSF1-regulated chaperones, particularly Hsp90, include numerous key players in classical tumorigenic pathways. HSF1 thus presents a promising therapeutic target for cancer treatment, potentially in combination with HSP inhibitors to alleviate typical initiation of HSR upon their use.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25014483
003      
CZ-PrNML
005      
20250905141321.0
007      
ta
008      
250701s2025 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s13008-025-00153-1 $2 doi
035    __
$a (PubMed)40287736
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Fiser, Otakar $u Research Centre for Applied Molecular Oncology (RECAMO), Masaryk Memorial Cancer Institute, Brno, Czech Republic $u Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic
245    10
$a Role of HSF1 in cell division, tumorigenesis and therapy: a literature review / $c O. Fiser, P. Muller
520    9_
$a Heat shock factor 1 (HSF1) is the master orchestrator of the heat shock response (HSR), a critical process for maintaining cellular health and protein homeostasis. These effects are achieved through rapid expression of molecular chaperones, the heat shock proteins (HSPs), which ensure correct protein folding, repair, degradation and stabilization of multiprotein complexes. In addition to its role in the HSR, HSF1 influences the cell cycle, including processes such as S phase progression and regulation of the p53 pathway, highlighting its importance in cellular protein synthesis and division. While HSF1 activity offers neuroprotective benefits in neurodegenerative diseases, its proteome-stabilizing function may also reinforce tumorigenic transformation. HSF1 overexpression in many types of cancer reportedly enhances cell growth enables survival, alters metabolism, weakens immune response and promotes angiogenesis or epithelial-mesenchymal transition (EMT) as these cells enter a form of "HSF1 addiction". Furthermore, the client proteins of HSF1-regulated chaperones, particularly Hsp90, include numerous key players in classical tumorigenic pathways. HSF1 thus presents a promising therapeutic target for cancer treatment, potentially in combination with HSP inhibitors to alleviate typical initiation of HSR upon their use.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Muller, Petr $u Research Centre for Applied Molecular Oncology (RECAMO), Masaryk Memorial Cancer Institute, Brno, Czech Republic. muller@mou.cz
773    0_
$w MED00173234 $t Cell division $x 1747-1028 $g Roč. 20, č. 1 (2025), s. 11
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40287736 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250701 $b ABA008
991    __
$a 20250905141309 $b ABA008
999    __
$a ok $b bmc $g 2388098 $s 1251603
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2025 $b 20 $c 1 $d 11 $e 20250426 $i 1747-1028 $m Cell division $n Cell Div $x MED00173234
GRA    __
$a 22-17102S $p Grantová Agentura České Republiky
GRA    __
$a MH CZ - DRO MMCI, 00209805 $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a project SALVAGE, P JAC; CZ.02.01.01/00/22_008/0 004 644 $p Ministerstvo Školství, Mládeže a Tělovýchovy
LZP    __
$a Pubmed-20250701

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...